![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/21161439-726418184-24511_25439_4546_v150-100x85.jpeg)
Roche’s Tecentriq retries for insurance coverage as adjuvant therapy after lung cancer surgery
Roche Korea has renewed its bid for health insurance coverage of its anti-PD-L1 immuno-oncology drug Tecentriq (atezolizumab) as an adjuvant therapy after surgery for early-stage non-small cell lung cancer (NSCLC). Industry insiders pay attention to see if …